Jul 8, 2024, 03:27
Timely genomic testing for lung cancer – EGFR Positive UK
EGFR Positive UK shared on X:
“EGFR and ROS-1 co-occurrence in lung cancer may be more common than thought.
Patients must have access to timely genomic testing for effective treatment paths. 40% of our community faced delays in mutation ID and only 40% were offered rebiopsy on progression.
Comment: EGFR+ patient data is from our 2024 Members’ Survey – the largest survey of UK EGFR patients. Sign up for early access and get the full survey report on Monday 8th July.”
Read further.
Source: EGFR Positive UK/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14